KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pacira BioSciences (PCRX) Income from Continuing Operations (2016 - 2025)

Pacira BioSciences (PCRX) has 16 years of Income from Continuing Operations data on record, last reported at 1637000.0 in Q4 2025.

  • For Q4 2025, Income from Continuing Operations fell 89.79% year-over-year to 1637000.0; the TTM value through Dec 2025 reached 7034000.0, up 107.07%, while the annual FY2025 figure was 7034000.0, 107.07% up from the prior year.
  • Income from Continuing Operations reached 1637000.0 in Q4 2025 per PCRX's latest filing, down from 5432000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 25763000.0 in Q2 2023 and bottomed at 143466000.0 in Q3 2024.
  • Average Income from Continuing Operations over 5 years is 364450.0, with a median of 7903500.0 recorded in 2022.
  • Peak YoY movement for Income from Continuing Operations: soared 1666.81% in 2023, then crashed 1421.29% in 2024.
  • A 5-year view of Income from Continuing Operations shows it stood at 5130000.0 in 2021, then tumbled by 96.92% to 10102000.0 in 2022, then soared by 346.19% to 24870000.0 in 2023, then crashed by 35.5% to 16041000.0 in 2024, then crashed by 89.79% to 1637000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Income from Continuing Operations were 1637000.0 in Q4 2025, 5432000.0 in Q3 2025, and 4847000.0 in Q2 2025.